CagriSema

Cagrilintide + Semaglutide research pairing · presentation must be confirmed per quote and lot

Component- and presentation-specific; confirm methods and released-lot results · target, verify batch COACAS 910463-68-2RUO

Research statusInvestigational fixed-dose clinical combination; US NDA submitted in December 2025 and the sponsor still described it as investigational in June 2026

Supplied formTwo-peptide reference pairing; the catalogue name is not a single chemical entity

Lead time14–21 days

CagriSema — Lot- and presentation-specific research material; confirm whether components are in separate containers or co-presented, and confirm each appearance on the released-lot documents

Representative packaging image · verify the ordered lot

Decision summary

Key benefits

Research relevance includes component-specific analytical qualification, amylin- and GLP-1-pathway assay design and evaluation of combination hypotheses
Clinical trial outcomes apply to the sponsor's finished formulation and protocol and do not establish performance, equivalence or safety of separate RUO lots.

Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS: 910463-68-2
Formula: Confirm supplied form on batch COA
Molecular weight: approximately 4113.6 g/mol
Appearance: Lot- and presentation-specific research material; confirm whether components are in separate containers or co-presented, and confirm each appearance on the released-lot documents
Purity: Component- and presentation-specific; confirm methods and released-lot results · target, verify batch COA
Storage: Use only the released-lot storage statement for the actual presentation. If components are separate, qualify each container independently; if they are co-presented, require mixture-specific stability, compatibility, pH, concentration, container and hold-time evidence. Do not infer any of these from the sponsor's finished formulation.
MOQ: On request
Lead time: 14–21 days

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Define long-term storage and transit exposure separately. Cold-chain can be quoted when the buyer’s risk assessment requires it and adds cost.

Research context

What researchers study about CagriSema

CagriSema is Novo Nordisk's investigational fixed-dose clinical combination of cagrilintide and semaglutide. This catalogue material is not the sponsor's finished formulation, and the exact research presentation—separate containers or co-presented material—must be confirmed on the quote and released-lot documents. The sponsor reported a US FDA NDA submission in December 2025, anticipated a decision in late 2026 and still described CagriSema as investigational in June 2026. FDA's current page states that cagrilintide is not a component of an approved drug and cannot be used in compounding under federal law. REDEFINE 4 did not meet its prespecified noninferiority endpoint versus tirzepatide.

Component identity and method development, GLP-1 and amylin/calcitonin receptor assays, and qualified in-vitro combination research
These are research applications, not clinical indications.

Mechanism context

The question the literature is testing

Semaglutide is a long-acting GLP-1 receptor agonist analogue; cagrilintide is a long-acting amylin analogue with amylin/calcitonin-receptor pharmacology. Their complementary clinical rationale is studied in the sponsor's formulation. Component identity, concentration, ratio, matrix and assay controls must be defined independently in laboratory research.

Evidence map

Research routes and exposure context

Evidence tierHuman clinical research

Research areaMetabolic and incretin research

Routes reported in sources

No administration route applies

Dose / exposure contextProtocol-specific; verify the cited primary source

Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

Not for human or veterinary use
This catalogue material is not the sponsor's finished clinical formulation and is not interchangeable with an approved semaglutide medicine, regardless of whether the research presentation is separate or co-presented
Follow the SDS and institutional controls
Chemical purity does not establish sterility, injectable suitability, formulation equivalence or clinical safety.

Interactions reported in the literature

Not established for separate Research Use Only components
No patient drug-interaction, stacking or oral-medication timing advice is provided.

Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Factory batch documentation

CagriSema factory batch COAs

CagriSema 5 mg Factory batch COA protected preview

CagriSema5 mg · WHJLP-CAGSM5-260630-E

CagriSema 10 mg Factory batch COA protected preview

CagriSema10 mg · WHJLP-CAGSM10-260630-E

CagriSema 20 mg Factory batch COA protected preview

CagriSema20 mg · WHJLP-CAGSM20-260630-E

Representative records, refreshed periodically

Published COAs show representative factory batches and may not be the latest available. For a current quote or shipment, our sales team can confirm the applicable lot and provide its COA.

Independent testing, arranged on request

Third-party reports are not routinely published. If independent verification is required, we can agree the laboratory, method, acceptance criteria and remedy before testing. If the agreed specification is not met, an appropriate resolution—including a refund where applicable—can be discussed under the agreed terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Help reviewing your COA

Need help reading a factory COA or third-party report? Our sales team can clarify test items, specifications and how the results relate to the lot under discussion.

Ask for the current packet, not a generic certificate

Require component-specific exact modified sequence and form, intact mass, sequence/modification evidence, stability-indicating RP-HPLC method, peptide content, related substances, counterion, water and residual solvents
For a co-presented material, methods must resolve and quantify both components and relevant impurities and verify the actual ratio
A blended purity number cannot replace component-level characterization.

Released-batch COARP-HPLC result and method contextIdentity result appropriate to the moleculeWater / counter-ion context where relevantSDS and handling statementAdditional testing scoped on request

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack

CASM-05MG5 mg10 vials

CASM-10MG10 mg10 vials

CASM-20MG20 mg10 vials

Handling

Storage in the lab and temperature during transit are different decisions

Use only the released-lot storage statement for the actual presentation. If components are separate, qualify each container independently; if they are co-presented, require mixture-specific stability, compatibility, pH, concentration, container and hold-time evidence. Do not infer any of these from the sponsor's finished formulation.

State destination, season, acceptable transit exposure and whether your protocol requires insulated or cold-chain service. Additional temperature-control cost is quoted explicitly.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. Testing must be performed by a mutually accepted, established specialist laboratory. Fee allocation, specification, sampling, method and acceptance rule must be agreed before testing; if an agreed independent result shows nonconformance, the remedy follows the signed order terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

Is cold-chain shipping always required?+

Not always. Heat can accelerate degradation, especially during summer and long transit. Cold-chain reduces exposure but raises cost. State the destination and stability risk so the right service can be quoted.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices IATA Temperature Control Regulations ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls

These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

Clinical evidence: REDEFINE 1 and 2 and the listed phase 2, regional and diabetes studies. Protocol traceability: ClinicalTrials.gov NCT05567796. Current milestones: Novo Nordisk announcements dated 18 December 2025, 23 February 2026 and 7 June 2026. Regulatory boundary: FDA's current unapproved-GLP-1 page. Component identity: FDA GSRS and authoritative component records. Results do not define an RUO mixing protocol.

01
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
The New England Journal of Medicine · 2025 · peer-reviewed original research (phase 3a randomized controlled trial)
Open source
02
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
The New England Journal of Medicine · 2025 · peer-reviewed original research (phase 3a randomized controlled trial)
Open source
03
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
The Lancet · 2023 · peer-reviewed original research (phase 2 randomized controlled trial)
Open source
04
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
The Lancet · 2021 · peer-reviewed original research (phase 2 randomized controlled trial)
Open source
05
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial
The Lancet Diabetes & Endocrinology · 2026 · peer-reviewed original research (phase 3a randomized controlled trial)
Open source
06
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study
The Lancet Diabetes & Endocrinology · 2026 · peer-reviewed original research (phase 3a randomized controlled trial)
Open source
07
Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians
Annals of Internal Medicine · 2026 · peer-reviewed systematic review and network meta-analysis (commissioned by a major medical professional society)
Open source
08
Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis
Journal of Diabetes & Metabolic Disorders · 2026 · peer-reviewed systematic review and meta-analysis
Open source

Product FAQ

Questions buyers ask about CagriSema

Do the CagriSema catalogue labels establish a pre-mixed or separate-component presentation?+

No. A variant label such as 2.5 mg + 2.5 mg states nominal component amounts but does not establish whether the materials are supplied in separate containers, co-lyophilized or otherwise co-presented. The quote, container/label record and released-lot COA must state the physical presentation, actual content acceptance range and test strategy for each component. Do not infer mixing, compatibility or concentration from the catalogue name.

Why does CagriSema not carry a single CAS?+

CagriSema names a combination of two distinct modified peptides, not one covalently defined molecule. Semaglutide and cagrilintide therefore retain separate registry identifiers, sequences, theoretical masses and supplied forms. A combination name or nominal total fill cannot establish either identity; require component-specific identity and quantitative-content evidence on the released-lot documents.

What is the analytical basis for treating the two components as a reference pairing?+

Require, rather than assume, exact modified sequence and form, high-resolution intact mass, sequence/modification evidence, stability-indicating chromatography, quantitative peptide content, counterion, water and residual solvents for each component. If the components are co-presented, the method must also demonstrate component-specific identity, ratio/content, relevant co-eluting impurities and matrix compatibility. A single blended HPLC area percentage or generic mass trace is insufficient.

CagriSema

Key benefits

Specifications to confirm against the released lot

Identity, purity and content are separate release questions.

What researchers study about CagriSema

The question the literature is testing

Research routes and exposure context

Compatibility, limitations and decision context

Interactions reported in the literature

CagriSema factory batch COAs

Ask for the current packet, not a generic certificate

Quote the fill and pack configuration you need

Storage in the lab and temperature during transit are different decisions

Terms to settle before the purchase order

Literature behind the research context

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity

Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial

Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial

Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial

Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study

Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians

Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis

Questions buyers ask about CagriSema

Compare adjacent molecules and documentation needs.

Cagrilintide

Semaglutide

Tirzepatide

Liraglutide